2025 ZAODX Early Screening Conference Successfully Concludes in Guangzhou, Showcasing Innovations and Cross-Integration of Traditional and Modern Medicine

December 20-21, 2025: The 2025 ZAODX Early Screening Conference was successfully held in Guangzhou.The ConferenceBringing together leading figures and professionals from the fields of government, industry, academia, research, investment, and healthcare,Through the main forum,Ten parallel thematic forums and an awards ceremony, spanning across“A Platform for Achievement Transformation and Industrial Exchange and Cooperation Covering the Full Chain of Prevention, Screening, Diagnosis, Treatment, and Rehabilitation.”

Through cutting-edge reports, roundtable dialogues, and showcases of achievements, industry experts engaged in in-depth discussions on technological innovation, translation of research findings, and pathways to universal access in the field of early screening, jointly outlining a new blueprint for the high-quality development of the early screening sector. According to statistics from the organizing committee, the conference attracted over 2,000 offline attendees, establishing itself as a key benchmark for gathering innovative elements, accelerating the translation of innovative achievements, and promoting the high-quality development of the industry.

Themed “Integrating Traditional Chinese and Western Medicine for a Disease-Free World,” this conference is jointly organized by the Guangdong Health Care Association, the Greater Bay Area Institute of Precision Medicine (Guangzhou), the Guangdong Nanshan Medical Innovation Research Institute, the Cancer Screening and Early Diagnosis and Treatment Professional Committee of the Guangdong Anti-Cancer Association, Cancer Screening and Prevention / Huayu Publishing House, the Cell Medicine Branch of the China Food and Drug Enterprise Quality and Safety Promotion Association, the Hainan Medical Innovation Promotion Association, the Beijing Chronic Disease Prevention and Health Education Research Association, the Western Digital Intelligence Medical Research Institute, the Guangzhou Lianchuang Mingyi Hospital of Traditional Chinese Medicine, the Guangzhou Development District Biopharmaceutical and Health Industry Promotion Association, Guangdong MedValley, and Zao Dx.

The conference was co-chaired by Professor Chen Wanqing, Professor Xing Jinliang, Professor Pan Kaifeng, Professor Tang Shiqi, Professor Zhang Qun, Professor Du Yiqi, Professor Lin Xinhua, Professor Zhang Kai, Professor Cao Sumei, Professor Wang Xiaoning, Professor Youlin Qiao, Professor Hu Kaiwen, Professor Chen Junhui, Professor Lu Guohui, Professor Xiao Guishan, Professor Pan Xinghua, and Professor Liren Li. The executive chairs were Ms. Sun Yuqing, Professor Liang Wenhua, Professor Qiu Mantang, Professor Luo Huaichao, Professor Ye Mingzhi, Professor Hou Zhibo, Professor Xia Kai, Professor Li Xiaosong, Professor Xiong Yufeng, Professor Lin Liming, Mr. Xu Mengchao, and Mr. Chen Zanquan.

Professor Chen Wanqing, Director of the Office of Cancer Registry at the National Cancer Center and Chair of the Committee on Cancer Prevention and Control of the China National Health AssociationAt the opening ceremony, it was stated that under the “Healthy China 2030” strategy, the cancer prevention and control system is undergoing a fundamental shift from being “treatment-centered” to being “people’s health-centered,” and that “early screening, early diagnosis, and early treatment” are key to reducing the disease burden and improving the overall health of the population.

In 2022, there were approximately 4.82 million new cancer cases and over 2.57 million cancer-related deaths in China. As a systematic public health initiative, early screening is both urgent and critical. The theme of this conference is “Integrating Traditional Chinese and Western Medicine for a Disease-Free World,” with a special “Ethnic Medicine Oncology Forum” established to integrate modern early screening technologies with the traditional wisdom of “preventive treatment of disease,” thereby exploring a new model of tumor prevention and control with Chinese characteristics.

Professor Chen also pointed out that the industry still faces challenges in terms of coverage, standardization, health economics, and public education. He called on all sectors to build consensus, foster a collaborative innovation ecosystem, and jointly promote the equitable access of scientific and technological achievements for the benefit of the public.

President of the Guangdong Health Care AssociationProfessor Wang ShengliangHe articulated three core insights: First, he emphasized revitalizing the ancient wisdom of Traditional Chinese Medicine (TCM) in “preventive treatment of disease” within the era of early screening, shifting health management from “disease detection” to “building a lifelong health barrier.” Second, he fully affirmed the strategic significance of establishing the “Ethnic Medicine Anti-Cancer Forum,” calling for a scientific approach to explore and validate the unique value of various ethnic medicines in cancer treatment, thereby offering “Chinese solutions” and “ethnic wisdom” to the world. Third, he advocated that the true merit of “integrating TCM with Western medicine” lies in deep fusion and collaborative action, promoting the practical combination of modern technology with TCM’s holistic perspective and syndrome differentiation in areas such as risk assessment and personalized intervention. He concluded by stressing that all explorations must ultimately “serve people,” and called on all sectors to adopt an open, inclusive, and pragmatic cooperative attitude to jointly advance the prevention and control of diseases upstream, thereby enhancing the health and well-being of the entire population.

Professor Barry Marshall, Winner of the 2005 Nobel Prize in Physiology or MedicineEmphasis: The severity of cancer as a major global public health challenge. He pointed out that early screening and diagnosis are the most effective strategies for reducing mortality rates and improving patients’ quality of life. Professor Marshall expressed particular appreciation for this year’s conference theme, “Integrating Chinese and Western Medicine for a Disease-Free World,” noting that combining modern precision medicine technologies with the ancient wisdom of Traditional Chinese Medicine’s “preventive treatment” approach can build a more comprehensive and robust system for cancer prevention and control, offering great hope for global health. He affirmed China’s achievements in promoting medical innovation and equitable access to healthcare, expressing confidence that this conference will further consolidate efforts, spur innovation, and accelerate collaboration, ultimately advancing the universal accessibility of cancer screening and creating a healthier future for all humanity.

Professor Hu Kaiwen, Academic Leader of the Department of Oncology at Dongfang Hospital of Beijing University of Chinese Medicine and Renowned TCM Physician of Beijingdelivered a keynote speech titled “AI-Empowered Traditional Chinese Medicine for the Prevention and Treatment of Pulmonary Nodules,” systematically sharing his team’s cutting-edge explorations and practical achievements in the deep integration of artificial intelligence (AI) with Traditional Chinese Medicine (TCM). In response to the large population of patients with pulmonary nodules in China and the prevailing dilemma of “predominant follow-up with limited intervention,” Professor Hu, centered on the TCM philosophy of “preventive treatment of disease,” combined radiomics, multimodal data, and large language model technologies to construct a precise assessment and prediction system for high-risk pulmonary nodules. This approach advances the advantageous TCM interventions to an earlier stage, prior to meeting surgical indications. Professor Hu also introduced progress in intelligent models based on CT imaging, facial features, and tongue images, as well as the implementation effectiveness of the “Digital TCM Service Platform” in real-world clinical and primary care settings. He demonstrated how AI is reshaping a new green prevention and treatment model for pulmonary nodules and even tumors—from auxiliary diagnosis and prescription decision-making to heritage and training—providing an innovative pathway with distinct TCM characteristics for early screening, early assessment, and early intervention.

At the Main Forum, Renowned TCM Practitioner of Beijing and Academic Leader of the Department of Oncology at Dongfang Hospital, Beijing University of Chinese MedicineProf. Kaiwen Hu, Vice President of Nanfang Hospital, Southern Medical UniversityProfessor Zheng Lei, experts from the School of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical CollegeProfessor Youlin Qiao, Founder and CEO of Xiangda BiotechDr. Yan Tao ZhaoKeynote speeches were delivered on traditional Chinese medicine for cancer treatment, disease biomarkers, cervical cancer screening, and cutting-edge technologies, presenting a multidimensional view of frontier early-screening technologies and integrated innovation. These discussions provided insightful and profound inspiration for building a comprehensive, full-cycle cancer prevention and control system.

During the conference’s roundtable discussion session, Mr. Chen Zanquan, Founder and CEO of Zao Dx, moderated the roundtable on the theme of “Opportunities and Challenges in Cancer Prevention and Control in China”, with participating guests including Mr. Zhong Jing, Investment Director at SDIC Venture Capital; Professor Nie Jinfu from the Hefei Institutes of Physical Science, Chinese Academy of Sciences; Mr. Yu Shaohua, General Manager of Aorui Biotechnology; Mr. Gao Shijun, Marketing & Medical Director at Genron Bio; and Dr. Xia Yingda, Head of AI Early Screening Algorithms at Alibaba DAMO Academy. The panelists engaged in in-depth dialogue from various perspectives, including technology, capital, clinical practice, and product development, fostering intellectual exchange and building consensus.

The conference also featured ten specialized vertical forums, constructing a comprehensive ecosystem spanning from technological frontiers to industrial implementation, with each session bringing together top scholars and industry leaders in the respective fields.

On the afternoon of December 20, by the Director of the Office of Cancer Registration at the National Cancer Center/Chairman of the Oncology Prevention and Control Professional Committee of the China National Health AssociationProf. Wanqing Chen, Qihuang Scholar, Renowned TCM Physician of Beijing, Academic Leader of the Department of Oncology at Dongfang Hospital of Beijing University of Chinese Medicine, and Former Vice PresidentProf. Kaiwen HuThe Ethnic Medicine Anti-Cancer Forum, with its chairman presiding, was held.

Deputy Director, Center for Integrative Medicine Research, Sun Yat-sen University Cancer CenterProfessor Li Liren, National Cancer Center / Special Committee on Tumor Prevention and Control of the China National Health AssociationProf. Li Jiang, Director of the Department of Oncology, China-Japan Friendship HospitalProf. Lou Yanni, Director of the Big Data Center, Beijing Hospital of Traditional Chinese MedicineProf. Bo Li, Director of the Beijing Tibetan Hospital, China Tibetology Research CenterProf. Luo Hui, President of Shenzhen Bao'an Pure Traditional Chinese Medicine Hospital (public tertiary-level, the first in China), and Doctoral SupervisorProf. Zhang Enxin, Oncology Center, The First Affiliated Hospital of Guangzhou University of Chinese MedicineProf. Hanrui Chen, School of Life Sciences, Beijing University of Chinese MedicineProfessor Jingxiao Wang, Dongfang Hospital of Beijing University of Chinese MedicineProf. Liu Chuanbo, Founder & CEO of MaituoyinDr. Li Shaochuan, Founder & CEO of Zao Dx / Vice President of the Guangdong Health Care AssociationMr. Chen Zanquanawaiting the attendance of guests.

As one of the most distinctive thematic forums this year,Deeply implementing the conference’s core theme of “Integrating Chinese and Western Medicine for a World Free of Disease,” this forum facilitates in-depth dialogue and exploratory integration between the traditional medical wisdom of “preventive treatment” and modern scientific approaches to cancer prevention and control. The hosting of this forum not only provides a high-level academic platform for the protection and inheritance of ethnic medical culture, but more importantly, it pioneers an innovative pathway for constructing a comprehensive cancer prevention and control model with Chinese characteristics that integrates multi-ethnic wisdom, serving as the most vivid practical testament to the conference’s theme of “Integrating Chinese and Western Medicine.”

On the afternoon of December 20, by the Director and Deputy Dean of Guangdong Nanshan Institute of Pharmaceutical InnovationDr. Xia Kai, Vice Dean of the Nansha Institute of Sun Yat-sen UniversityProfessor Ye MingzhiThe Longevity Medicine and New Technologies for Health Screening Forum, with its chair presiding, was held.

Former Inspector of the Guangdong Provincial Health and Family Planning Commission, Former Deputy Director of the Guangdong Provincial Department of HealthProfessor Liao Xinbo, Medical Director of AmisonDr. Li Tingting, General Manager of the Digital Intelligence Innovation Department, Beijing Dongfang Insurance Brokers Co., Ltd.Mr. Sun Jingxuan, Head of the Multi-Omics Department at Boercheng MedicineDr. Du Baochen, Founder & CEO of MegaGeneMr. Xia Yudong, Medical Director at Aorui BiomedicalDr. Li Xiaomo, Marketing & Medical Director at Kunyuan BioMr. Gao Shijun, Academic Marketing Director, Jingyi Weixiang (Shanghai) Health Industry Development Co., Ltd.Mr. Feng Qile, Dean of Du Anquan Guangzhou Outpatient Internet HospitalMr. Xu Jiequn, CEO & Clinical Director of Deneng MedicalMr. Liu XiaoweiAwaiting the attendance of guests.

This forum accurately captures the contemporary trend of shifting from “disease treatment” to “health maintenance,”The forum systematically explored cutting-edge pathways for extending from early disease screening to health and longevity management. Attendees shared in-depth insights on the application of biomarkers such as exercise interventions and DNA methylation in quantifying aging and enabling early detection of multiple cancer types. They also highlighted practical achievements in the early diagnosis of key diseases, including liver cancer, through liquid biopsy, multi-target ctDNA methylation testing, and artificial intelligence models.。

On the afternoon of December 20, by Bowen Biology’s founder and CEOMr. Lin Liming, General Manager of Miaoxin BiotechnologyMr. Xu MengchaoThe 2025 Medical-Grade Genetic Testing Conference and AI-Driven Proactive Health Ecosystem Conference, with the Forum Chair presiding, was held.

Deputy General Manager of Miaoxin BioMr. Wang Leyu, Director of Hunan Women and Children's HospitalProfessor Wu Jinxiu, Director of the Department of Pharmacology, Guangdong Pharmaceutical UniversityProfessor Liu Song, President of Huasheng Medical Group’s Beijing Chaoyang CampusProf. Gui-Ping Ge, General Manager of Huiyuan GeneticsMr. Ma Minrui, Director of the Department of Laboratory Medicine, School of Medicine, Hebei University of EngineeringProf. Wang Zhen, Head of MJKNO MedicineMs. Wang Pengpeng, Health Management Director, Global Anti-Aging Physicians GroupMs. Xu Qian,Founding President, Guangdong Association for the Promotion of Knowledge Economy Development (September 2015)Mr. Gu QizhiAwaiting the arrival of guests.

At the meeting,The Plaque-Awarding Ceremony for Medical-Grade Genetic Testing Alliance Units in the Era of Universal Genomics Was Officially Held.Genetic testing is advancing into a new “medical-grade” phase centered on clinical credibility, medical interpretation frameworks, and long-term health management, promoting the standardized application of genetic data in real-world clinical and health management settings, and exploring the systemic value of genetic information in disease risk assessment, early warning, personalized intervention, and long-term follow-up.

This forum precisely focuses on the deep integration of “medical-grade” genetic testing and artificial intelligence technologies, aiming to transcend traditional consumer-grade genetic testing and single-dimensional health assessment models. It seeks to build a new ecosystem for proactive health that encompasses “data generation, intelligent interpretation, personalized intervention, and continuous management,” thereby laying a solid foundation of industry consensus and collaboration for the large-scale, intelligent implementation of proactive health.

On the morning of December 21, by the Cancer Hospital of the Chinese Academy of Medical SciencesProf. Wanqing Chen, Peking University Cancer HospitalProfessor Pan KaifengThe AI and Multi-Cancer Early Detection Forum, chaired by [Name/Entity], was held.

Tianjin Medical University Cancer Institute and HospitalProfessor Chen Kexin, Hefei Institutes of Physical Science, Chinese Academy of SciencesResearcher Hong Bo,The Fourth Hospital of Hebei Medical UniversityProfessor Yu-Tong He, Hefei Institutes of Physical Science, Chinese Academy of SciencesProfessor Nie Jinfu, Sun Yat-sen University Cancer CenterProf. Luo Huiyan, Peking University Cancer HospitalProf. Li Wenqing, Nanjing Medical UniversityProfessor Ma Hongxia, Senior Algorithm Expert and Professor at the Medical AI Lab of DAMO AcademyDr. Yingda XiaAwaiting the arrival of guests.

This forum systematically presented the latest research advances and practical explorations of AI and big data in early cancer screening. Participating experts, drawing on the construction of global pan-cancer risk databases, the scientific frontiers of multi-cancer early detection (MCED), and application achievements in key cancers such as lung and gastric cancer through radiomics, radiogenomics, and non-contrast CT combined with AI technologies, engaged in in-depth discussions on pathways toward shifting risk assessment earlier, implementing multi-cancer joint screening, and achieving precision prevention.

On the morning of December 21, led by the academic discipline leader of the Health Management Center at Renmin Hospital of Wuhan University,Former Vice Chairman, Health Management Branch of the Chinese Medical AssociationProf. Tang Shiqi, President-Elect of the Health Management Branch of the Chinese Medical Association, and Director of the Health Management Center at Jiangsu Province People’s HospitalProf. Zhang QunThe Forum on Cancer Prevention Health Checkups and Early Screening and Diagnosis Clinics, with the role of forum chair, was held.

Director, Office of Cancer Registration, National Cancer CenterProfessor Wanqing Chen，Editor-in-Chief of *Cancer Screening and Prevention*; Deputy Director, Department of Gastroenterology, Changhai Hospital, Naval Medical UniversityProf. Du Yiqi, Director of the Health Management Center, Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and TechnologyProfessor Xu Sanping, Director of the Department of Health Medicine, the First Affiliated Hospital of Xi'an Jiaotong University School of MedicineProfessor Ma Mao, Director of the Department of Cancer Prevention, National Cancer Center/Cancer Hospital, Chinese Academy of Medical SciencesProf. Zhang Kai, Director of the Health Management Center, Zhongshan Hospital Affiliated to Fudan University; Member of the Physical Examination and Assessment Group, Health Management Branch, Chinese Medical AssociationProf. Sunfang Jiang, Director of the Health Management Center, Nanfang Hospital of Southern Medical University; Director of the Guangdong Provincial Quality Control Center for Professional Health Examination ManagementProf. Liu Li, Director of the Health Management Department at the First Affiliated Hospital of China Medical University, and Standing Committee Member of the Professional Committee on Physician Health Management and Physician Health Insurance under the Chinese Medical Doctor AssociationProf. Wang Wei, Director of the Physical Examination Center, The First Affiliated Hospital of Harbin Medical University; Standing Committee Member, Health Management Branch, Chinese Medical AssociationProf. Fu Jun, Director of the Health Management Center, Xuanwu Hospital, Capital Medical UniversityProfessor Chu Xi, Executive Deputy Secretary-General of the Committee on Physician Health Management and Health Insurance, Chinese Medical Doctor AssociationProf. Wu Fei, Deputy Secretary-General of the Guangdong Provincial Society for Precision Medicine ApplicationProf. Chen Ran, Party Branch Secretary of the Health Management Center, Nanfang Hospital, Southern Medical UniversityProf. Guangqing Zhou, Attending Physician at Renmin Hospital of Wuhan UniversityProf. He Lu, Attending Physician at Jiangsu Province HospitalProfessor Lu Jing, Lecturer at Nanjing Medical UniversityProfessor Yu ChengxiaoAwaiting the arrival of guests.

At the conference, the “Expert Consensus on the Application of Liquid Biopsy Technology in Health Management” was officially launched.This consensus aims to systematically review the scientific basis, application scenarios, and practical pathways of liquid biopsy technology in health management and early disease screening, thereby promoting the transition of related technologies from research exploration to standardized, normalized, and scalable implementation. The content will focus on key issues such as selection of detection technologies, definition of target populations, interpretation of results, risk stratification, and follow-up management. It provides professional guidance for the rational application of liquid biopsy in physical examination centers, primary healthcare settings, and public health systems, facilitating the better integration of early screening technologies into lifelong health management.

This forum centers aroundIn-depth discussions were held on core issues such as early prevention and control of multiple cancer types, the promotion of opportunistic screening, optimization of cancer-prevention health examination models, and the standardized development of early screening clinics. China’s cancer early screening efforts are accelerating from a phase of technological innovation and pilot exploration toward a new stage of systematic, standardized, high-quality services. In the future, cancer-prevention health examinations and early screening clinics are expected to become regular, inclusive components of the healthcare service system.

On the morning of December 21, by the Director of the Comprehensive Diagnosis and Treatment Ward for Thoracic Tumors at the First Affiliated Hospital of Guangzhou Medical University, and Vice President of Hengqin HospitalProf. Wenhua Liang, Deputy Director of the Peking University Institute for Thoracic OncologyProfessor Qiu MantangThe Forum on Innovation and Translation in Early Cancer Screening, and the Forum on Pulmonary Nodule Management and Lung Cancer Screening, chaired by the Forum Chair, was held.

Director, Health Management Center, Guangzhou First People's HospitalProfessor Yin Longyan,Director, Department of Cancer Prevention and Control, Zhejiang Cancer HospitalProfessor Du Lingbin, Investment Director at SDIC Venture CapitalMr. Zhong Jing, Director of the Department of Cancer Prevention, National Cancer Center/Cancer Hospital, Chinese Academy of Medical SciencesProfessor Zhang Kai, General Manager of Xiangda Biology China RegionMr. Guan Xin, Sullivan Life Sciences Consulting ManagerMs. Jing Jing, Founder of AmpakDr. Chang Yu, Head of the Clinical Research Group and Head of the Digestive System Disease Diagnosis Group, Department of Laboratory Medicine, Nanfang Hospital, Southern Medical UniversityProf. Xiong Yufeng, Vice Dean of the School of Laboratory Medicine, Chongqing Medical University, and Executive Dean of the Western Institute of Digital Intelligence HealthcareProf. Li XiaosongGuests are in attendance.

This forum not only provides a comprehensive perspective, from practice to theory, on the precision management of pulmonary nodules and early screening for lung cancer, but also deeply analyzes the core challenges and solutions involved in translating early screening achievements from the laboratory to the market, thereby powerfully promoting in-depth dialogue and collaboration among research, clinical practice, and industry.

On the afternoon of December 21, by the Executive Dean of the Guangdong-Hong Kong-Macao Greater Bay Area Institute of Precision Medicine (Guangzhou)Professor Lin Xinhua, Foreign Academician of the Russian Academy of Engineering, Shenzhen University of Advanced Technology, and Shenzhen Weilan Institute for Translational Research in Small Molecule Technologies (Preparatory)Professor Xiao GuishanThe Forum on Tumor Multi-omics Research and Translation, with Co-Chairs, Was Held.

General Manager, Xiamen Mailiao Technology Co., Ltd.Dr. Li Jia, Deputy Chief Technician, Department of Laboratory Medicine, Sichuan Cancer Hospital; Master’s SupervisorProf. Luo Huaichao, Deputy Director of the Marshall Biomedical Engineering Laboratory at Shenzhen University and the Shenzhen Nobel Prize Scientists LaboratoryProfessor Hou Zhibo, Director of the Department of Oncology, Peking University Shenzhen HospitalProfessor Wang ShubinWaiting for guests to attend.

This ForumIt not only demonstrates the powerful capabilities of cutting-edge models and tools in simulating the tumor microenvironment and deciphering immune responses, but also focuses on how these findings can be translated into clinical protocols for assisted diagnosis (such as the differentiation of indeterminate pulmonary nodules) and treatment guidance. Today, oncology research has entered a new stage characterized by the deep integration of multi-omics data and the acceleration of translational applications into clinical practice through advanced modeling.

On the afternoon of December 21, by the Director of the Cancer Prevention Department at the National Cancer Center/Cancer Hospital, Chinese Academy of Medical SciencesProfessor Zhang KaiFounding Director of the Interventional and Cell Therapy Center, Peking University Shenzhen Hospital; Founding President of the Cell Medicine Branch, China Food and Drug Promotion AssociationProfessor Chen JunhuiCo-Chairing the Longevity Medicine and Cell Therapy Forum & The 7th CGT Disruptive Technology Innovation ForumGo。

Deputy Director, National Clinical Center for Geriatric Diseases, Chinese PLA General Hospital (301 Hospital)Prof. Wang Xiaoning, School of Biomedical Sciences and Engineering, South China University of TechnologyProfessor Fu Xiaoling, Chairman and Chief Scientist of Gaomei Gene Technology Co., Ltd.Prof. Deqiang SunDirector of the Health Management Center, Nanfang Hospital of Southern Medical University; Director of the Guangdong Provincial Quality Control Center for Professional Health Examination ManagementProf. Liu Li, Standing Committee Member of the Health Emergency Professional Committee, Chinese Research Hospital AssociationProf. Liu BaochiDeputy Secretary-General and Director of the Office, Cell Medicine Branch, China Food and Drug Safety Promotion AssociationDr. Yanwei Xu, Director of Biotechnology at Kairui MeiDr. Li Kai，Fosun Pramerica – Senior Team Leader, Insurance & Private BankingMr. Zhao Jinlong, BD Director at Enze KangtaiMs. Zhihong Zhu, General Manager of Guangdong Kangming GroupProfessor Li ShuguangAwaiting the attendance of guests.

This forum has clearly outlined the transformative landscape in which cell and gene therapy technologies are transcending the scope of traditional disease treatment and expanding into the realms of proactive health maintenance and aging intervention, thereby building critical consensus and momentum to foster a new ecosystem for longevity medicine characterized by policy support, technology-driven innovation, and clinical validation.

On the afternoon of December 21, by a Professor at the Center for Precision Regenerative Medicine, Faculty of Medicine, Macau University of Science and Technology; Doctoral Supervisor at the Faculty of Medicine and Faculty of Pharmacy; and Mentor for Young Scholars in MacauProfessor Pan Xinghua, formerly of The University of Texas MD Anderson Cancer Center and Zhujiang Hospital of Southern Medical UniversityProfessor Lu Guohui (ABMG)Co-ChairThe 4th International Conference on the Prevention and Control of Hereditary Tumors and the Forum on the Application and Exploration of Regenerative Medicine in Tumor Prevention and Control Were Held.

Obstetrics and Gynecology Hospital of Fudan UniversityProfessor Kang Yu, Reproductive Medicine Center, First Affiliated Hospital of Naval Medical University (Shanghai Changhai Hospital)Professor Hongli Yan, Department of Colorectal Surgery, Sun Yat-sen University Cancer CenterProf. Wu Jiang, Deputy Director of the Department of Prevention and Treatment at Zhejiang Cancer Hospital, and Dual-Appointed Principal Investigator (PI) at the Hangzhou Institute for Advanced Study, University of Chinese Academy of SciencesProfessor Chen Tianhui, Founder of Shidai Chuancheng Gene TechnologyDr. Qu Ben, Vice President of BGI Group and Executive Dean of BGI Wisdom Medical Research InstituteDr. Shida ZhuAwaiting the arrival of guests.

The forum focused on hereditary tumors with familial aggregation, systematically exploring a comprehensive prevention and control strategy spanning the entire chain from genetic testing and genetic counseling to family management and clinical decision-making. Meanwhile, the forum proactively introduced the disruptive field of regenerative medicine, investigating the revolutionary potential of organoid models, stem cell technologies, and other approaches in simulating hereditary carcinogenesis, conducting drug screening, and repairing treatment-induced damage. This forum not only consolidated consensus on standardized prevention and control of hereditary tumors but also, with its unique dual focus on “prevention and control plus exploration,” pioneered an integrated new paradigm for cancer prevention and treatment—from precise risk identification to the research and development of proactive interventions—significantly advancing the field toward a more forward-looking and systematic direction.

 The award ceremony for the 4th Golden Screening Awards was held at the conference. The awards aim to recognize enterprises, products, institutions, and individuals that have made outstanding contributions to the field of early screening, inspiring all practitioners to forge ahead and jointly promote the widespread adoption and application of early screening technologies.

The 4th Golden Screening Awards Ceremony was held concurrently with the conference, serving as a key segment to convey the industry’s warmth and innovative strength at the event. The Golden Screening Awards pay tribute to institutions and individuals who have remained deeply committed to the field of early cancer screening, upheld their original aspirations, and actively promoted the development of early screening technologies and industry progress. The awards not only highly recognize their past perseverance and contributions but also fully affirm the innovative spirit and sense of responsibility across the entire early screening industry.

Standing at a critical juncture in the deepening implementation of the “Healthy China 2030” strategy, the ZAODX Early Screening Conference will adopt a more open posture and take more pragmatic actions to gather global innovative forces, build bridges for industrial collaboration, and accelerate the translation of innovative achievements, fully realizing the grand vision of “health screening accessible to all.” With joint efforts from all sectors, the early screening industry will enter a new stage of development characterized by greater standardization, innovation, and inclusiveness, injecting continuous momentum into reducing the national disease burden and improving the health status of the population.

2025 ZAODX Early Screening Conference - International Symposium will be held online on January 22, 2026. Stay tuned!

Let us look forward to reuniting at the 5th Early Screening Conference in 2026, joining hands to embark on a new journey toward equitable health access, and steadily advancing toward the noble vision of “A World Free of Disease.”